Product Name
IFT122, siRNA
Full Product Name
IFT122 siRNA (Human)
Product Synonym Names
SPG; WDR10; WDR140; Intraflagellar transport protein 122 homolog; WD repeat-containing protein 10; WD repeat-containing protein 140
Product Gene Name
IFT122 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9HBG6
Specificity
IFT122 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human IFT122 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of IFT122 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
IFT122 sirna
siRNA to inhibit IFT122 expression using RNA interference
Applications Tested/Suitable for IFT122 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for IFT122. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001267470.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001280541.1
[Other Products]
UniProt Primary Accession #
Q9HBG6
[Other Products]
UniProt Secondary Accession #
Q53G36; Q8TC06; Q9BTB9; B3KW53; B4DEY9; B4DPW7; E7EQF4; E9PDG2; E9PDX2; G3XAB1; H7C3C0[Other Products]
UniProt Related Accession #
Q9HBG6[Other Products]
Molecular Weight
113,230 Da
NCBI Official Full Name
intraflagellar transport protein 122 homolog isoform 5
NCBI Official Synonym Full Names
intraflagellar transport 122
NCBI Official Symbol
IFT122 [Similar Products]
NCBI Official Synonym Symbols
CED; SPG; CED1; WDR10; WDR10p; WDR140
[Similar Products]
NCBI Protein Information
intraflagellar transport protein 122 homolog
UniProt Protein Name
Intraflagellar transport protein 122 homolog
UniProt Synonym Protein Names
WD repeat-containing protein 10; WD repeat-containing protein 140
Protein Family
Intraflagellar transport protein
UniProt Gene Name
IFT122 [Similar Products]
UniProt Synonym Gene Names
SPG; WDR10; WDR140 [Similar Products]
UniProt Entry Name
IF122_HUMAN
NCBI Summary for IFT122
This gene encodes a member of the WD repeat protein family. WD repeats are minimally conserved regions of approximately 40 amino acids typically bracketed by gly-his and trp-asp (GH-WD), which may facilitate formation of heterotrimeric or multiprotein complexes. Members of this family are involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. This cytoplasmic protein contains seven WD repeats and an AF-2 domain which function by recruiting coregulatory molecules and in transcriptional activation. Mutations in this gene cause cranioectodermal dysplasia-1. A related pseudogene is located on chromosome 3. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2013]
UniProt Comments for IFT122
IFT122: Required for cilia formation and Shh signaling during neuronal patterning. Defects in IFT122 are a cause of cranioectodermal dysplasia type 1 (CED1). CED1 is a disorder characterized by craniofacial, skeletal and ectodermal abnormalities. Clinical features include dolichocephaly (with or without sagittal suture synostosis), scaphocephaly, short stature, limb shortening, short ribs, narrow chest, brachydactyly, renal failure and hepatic fibrosis, small and abnormally shaped teeth, sparse hair, skin laxity and abnormal nails. 4 isoforms of the human protein are produced by alternative splicing.
Chromosomal Location of Human Ortholog: 3q21
Cellular Component: membrane; cytoplasm; photoreceptor connecting cilium; cilium
Molecular Function: protein binding
Biological Process: limb development; embryonic forelimb morphogenesis; organelle organization and biogenesis; signal transduction downstream of smoothened; embryonic body morphogenesis; camera-type eye morphogenesis; negative regulation of smoothened signaling pathway; neural tube closure; cilium biogenesis; embryonic heart tube development; embryonic digit morphogenesis; negative regulation of epithelial cell proliferation; negative regulation of smoothened signaling pathway in ventral spinal cord patterning
Disease: Cranioectodermal Dysplasia 1
Research Articles on IFT122
1. this study was able to find causative IFT122 mutations in a non-consanguineous family with recurrent abortions.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
